ArticleBMC urology2025
The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder cancer: a retrospective analysis.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor-infiltrating lymphocytes (TILs) are integral components of the tumor microenvironment and have been extensively studied across various cancers. In bladder cancer, the prognostic significance of TILs remains uncertain. This study aimed to analyze the impact of muscularis mucosa invasion and TILs ratios on clinical outcomes, tumor aggressiveness, and prognosis in pT1 urothelial carcinoma of the bladder.
methodsThis retrospective study included 154 patients with pT1 bladder urothelial carcinoma, categorized into pT1a and pT1b groups based on the extent of muscularis mucosa invasion. TILs ratios were stratified into three groups: <1%, 1-5%, and > 5%. Clinical and pathological characteristics, including tumor diameter, necrosis, tumor thickness, recurrence, and progression rates, were compared. Depth of invasion and tumor features were assessed using standard histopathological methods. Recurrence and progression-free survival (PFS) were evaluated during a median follow-up of 20 months.
resultsBy definition, pT1b tumors demonstrated significantly deeper invasion into the muscularis mucosa (p < 0.0001) compared to pT1a tumors. They were also associated with larger tumor diameter (p = 0.023), greater tumor thickness (p < 0.0001), and increased necrosis (p = 0.0012). Radical cystectomy was performed more frequently in pT1b patients (19.2%) than in pT1a patients (7.9%), although recurrence and PFS rates did not differ significantly between the groups. Higher TILs ratios were linked to increased tumor thickness (p = 0.0299) and more extensive invasion into TURBT chips (p = 0.0025), but no significant differences in recurrence or PFS rates were observed across TILs groups.
conclusionsMuscularis mucosa invasion is a defining feature of pT1b bladder cancer and serves as a key indicator of tumor aggressiveness. While TILs were associated with aggressive tumor characteristics, their prognostic role remains inconclusive. These findings highlight the need for aggressive management strategies for pT1b disease and underscore the importance of further research into the complex interplay between TILs and tumor progression in bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.